Value
8.5/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 7.8 |
| Analyst target | 9.0 |
- ▸Attractively valued
IMCR · Why this verdict
Why Immunocore Holdings (IMCR) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.7/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Analyst consensus implies nearly 93% upside to the near-term price target and the risk/reward ratio is highly asymmetric on paper, but the business quality sits below the minimum acceptable threshold, the stock is in a confirmed downtrend with a death cross in place, and near-total revenue dependence on a single product in a single geography creates concentration risk that limits conviction until technical conditions improve.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The company's quality score sits at 3 out of 10 — below the 4-point minimum that would qualify it for a new position — with near-zero return on assets, return on equity, and margins well below industry norms, reflecting a business that has not yet achieved sustainable profitability. Quality | Quality score rises above 4.0 for 2 consecutive assessment periods, indicating that profitability metrics have improved enough to meet the minimum standard for investment consideration. | →Stable |
| CounterEarly-stage biotechnology businesses routinely run at negative margins while advancing a commercial asset; the current quality reading may not reflect long-term earning potential if the lead product gains market share and the cost structure begins to leverage. | ||
Revenue is highly concentrated in a single product and a single geography, meaning any setback in that product's commercial trajectory or a shift in the US market environment could have an outsized and immediate impact on the entire business. Bear case | A second approved product or meaningful international revenue begins contributing to total revenue, such that the leading product represents less than 80% of total sales. | →Stable |
| CounterConcentrated revenue from a single successful product can also reflect genuine commercial leadership and pricing power in a defined market; if the product's growth rate is healthy, concentration may not translate to fragility in the near term. | ||
The stock is trading below its 200-day moving average with the moving average itself trending lower at roughly 2% over the past 30 days, placing the chart in a confirmed downtrend — a technical condition that creates a structural headwind for near-term price recovery regardless of fundamental improvement. Momentum | The stock reclaims and holds above the 200-day moving average for 30 consecutive days, signaling that the downtrend has been broken and technical conditions have shifted. | →Stable |
| CounterMACD is improving and RSI sits near 44, suggesting internal momentum may be bottoming even while the price remains below the long-term trend line — a developing recovery could precede a formal trend reversal by several weeks. | ||
Analyst consensus implies roughly 122% upside from the current price, and the risk/reward ratio from the current price to the near-term target is approximately 10-to-1 in the favorable direction — creating asymmetric potential if the downtrend reverses and the product thesis plays out. Sentiment | Stock price advances more than 30% toward the analyst target over 12 months, validating the upside thesis without requiring a full consensus move. | →Stable |
| CounterWide analyst-implied upside in a confirmed downtrend with below-minimum quality often reflects a mismatch between sell-side optimism and fundamental execution rather than a true margin of safety — a rich asymmetry ratio can persist without ever resolving in the long direction if catalysts fail to materialize. | ||
The company's quality score sits at 3 out of 10 — below the 4-point minimum that would qualify it for a new position — with near-zero return on assets, return on equity, and margins well below industry norms, reflecting a business that has not yet achieved sustainable profitability.
→StableQuality
- Expectation
- Quality score rises above 4.0 for 2 consecutive assessment periods, indicating that profitability metrics have improved enough to meet the minimum standard for investment consideration.
CounterEarly-stage biotechnology businesses routinely run at negative margins while advancing a commercial asset; the current quality reading may not reflect long-term earning potential if the lead product gains market share and the cost structure begins to leverage.
Revenue is highly concentrated in a single product and a single geography, meaning any setback in that product's commercial trajectory or a shift in the US market environment could have an outsized and immediate impact on the entire business.
→StableBear case
- Expectation
- A second approved product or meaningful international revenue begins contributing to total revenue, such that the leading product represents less than 80% of total sales.
CounterConcentrated revenue from a single successful product can also reflect genuine commercial leadership and pricing power in a defined market; if the product's growth rate is healthy, concentration may not translate to fragility in the near term.
The stock is trading below its 200-day moving average with the moving average itself trending lower at roughly 2% over the past 30 days, placing the chart in a confirmed downtrend — a technical condition that creates a structural headwind for near-term price recovery regardless of fundamental improvement.
→StableMomentum
- Expectation
- The stock reclaims and holds above the 200-day moving average for 30 consecutive days, signaling that the downtrend has been broken and technical conditions have shifted.
CounterMACD is improving and RSI sits near 44, suggesting internal momentum may be bottoming even while the price remains below the long-term trend line — a developing recovery could precede a formal trend reversal by several weeks.
Analyst consensus implies roughly 122% upside from the current price, and the risk/reward ratio from the current price to the near-term target is approximately 10-to-1 in the favorable direction — creating asymmetric potential if the downtrend reverses and the product thesis plays out.
→StableSentiment
- Expectation
- Stock price advances more than 30% toward the analyst target over 12 months, validating the upside thesis without requiring a full consensus move.
CounterWide analyst-implied upside in a confirmed downtrend with below-minimum quality often reflects a mismatch between sell-side optimism and fundamental execution rather than a true margin of safety — a rich asymmetry ratio can persist without ever resolving in the long direction if catalysts fail to materialize.
Per-dimension breakdown
Quality
3.0/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 2.5 |
| Op margin | 2.7 |
| Net margin | 0.0 |
| Current ratio | 8.8 |
| Moat | 4.2 |
| Piotroski F | 5.6 |
- ▸No competitive moat
- ▸Quality concerns
Growth
8.0/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 5.9 |
| EPS growth | 10.0 |
Momentum
6.0/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.4 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 6.0 |
| Volume | 0.7 |
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA, MA slope -1.9%/30d — confirmed downtrend
Sentiment
6.6/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 10.0 |
| erm sentiment | 5.0 |
- ▸Analyst upside: 103%
Insider
5.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
Peer rank
4.7/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 8.7 |
| quality rank | 5.5 |
| growth rank | 4.4 |
Technical
2.1/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.0 |
| support resistance | 0.9 |
| 52w position | 5.3 |
Risk (lower is worse)
4.0/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.6 |
| days to cover | 0.0 |
| volatility | 3.0 |
| put call | 5.3 |
| implied vol | 2.0 |
| max pain risk | 7.0 |
| beta | 8.5 |
| debt equity | 4.8 |
- ▸High short interest justified: 19%
- ▸High IV: 68%
- ▸Concentration risks: 2 HIGH, 1 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
5.8/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (8)
- MOMENTUM:6.0>=5.5
- ASYMMETRY:6.6>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:42d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (1)
- DEATH_CROSS:momentum=6.0>=5.0 recovering
Reward-to-Risk
6.60
Upside
+76.9%
Downside
11.7%
Sizing output
AVOID
SetupRECOVERY — Death cross but MACD improving, RSI 66
EdgeNO_EDGE — No clear edge identified
SuitabilityAGGRESSIVE — MCap $1.5B<$5B
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Value at 8.5 could not lift the engine output above the verdict floor.
The strongest dimensions are Value at 8.5, Growth at 8.0, and Sentiment at 6.6; the weakest are Technical at 2.1, Quality at 3.0, and Risk (lower is worse) at 4.0. The V9 engine cleared all gates with 1 warning, producing an asymmetric reward-to-risk of 6.60 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1The company's quality score sits at 3 out of 10 — below the 4-point minimum that would qualify it for a new position — with near-zero return on assets, return on equity, and margins well below industry norms, reflecting a business that has not yet achieved sustainable profitability.
Trip ifQuality score rises above 4.0 for 2 consecutive assessment periods, clearing the minimum threshold.
- P2Revenue is highly concentrated in a single product and a single geography, meaning any setback in that product's commercial trajectory or a shift in the US market environment could have an outsized and immediate impact on the entire business.
Trip ifRevenue from a second product or international markets exceeds 20% of total revenue in any reported quarter.
- P3The stock is trading below its 200-day moving average with the moving average itself trending lower at roughly 2% over the past 30 days, placing the chart in a confirmed downtrend — a technical condition that creates a structural headwind for near-term price recovery regardless of fundamental improvement.
Trip ifStock price closes above the 200-day moving average and holds above it for 30 consecutive calendar days.
- P4Analyst consensus implies roughly 122% upside from the current price, and the risk/reward ratio from the current price to the near-term target is approximately 10-to-1 in the favorable direction — creating asymmetric potential if the downtrend reverses and the product thesis plays out.
Trip ifAnalyst consensus price target falls below $40, implying less than 40% upside from the current price level.